The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan
In this analysis, tirzepatide 5 mg was associated with an ICER below the commonly quoted willingness-to-pay threshold of JPY 5,000,000 per QALY gained, suggesting that tirzepatide is a cost-effective treatment option for adult patients with type 2 diabetes mellitus, compared with dulaglutide 0.75 mg.
Authors
- Masakazu Takeuchi (ORCID: https://orcid.org/0000-0003-3176-3118)
- Beatrice Osumili (ORCID: https://orcid.org/0000-0002-5862-9325)
- Takashi Kadowaki (ORCID: https://orcid.org/0000-0002-5428-3582)
- Manaka Sato (ORCID: https://orcid.org/0000-0001-7000-4769)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Barnaby Hunt (ORCID: https://orcid.org/0000-0001-5420-279X)
- Alice Minghetti (ORCID: https://orcid.org/0000-0001-7913-5861)
- Toshihiko Aranishi (ORCID: https://orcid.org/0000-0001-8862-9468)
- Zhihong Cai (ORCID: https://orcid.org/0000-0002-3431-197X)
- K. Hara
- Aska Mizogaki
Institutions
- Jichi Medical University (JP)
- Eli Lilly (United Kingdom) (GB)
- Eli Lilly (Japan) (JP)
- Department of Health (IE)
- Jichi Medical University Saitama Medical Center (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1007/s13300-024-01675-7
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Eli Lilly and Company